Good Morning Meeting – Using a ‘virtual pharma model’ to attract targeted investors for biotech innovators
Welcome to Medicon Valley Alliance Good Morning Meeting with Syneos Health on:
Using a ‘virtual pharma model’ to attract targeted investors for biotech innovators
De-risk investment, de-risk operational delivery and maximize the return on investment (ROI) for all parties
How to position your organization for fundraising using a virtual pharma partner model – Using the ‘two heads are better than one’ approach to investor outreach, coupled with support for clinical and commercial strategy, the integration of commercial thinking into your late phase clinical plans, and a robust use of funds built from the ground up using actual budgets is an attractive proposition for investors.
We will discuss our Capital Solutions approach with case studies, and we will also hear the perspective of an investor in the space to this approach.
Date: Wednesday October 2nd 2019
Time: 8:30 – 10:30
Venue: Medicon Valley Alliance, Arne Jacobsens Allé 15, 2300 Copenhagen S, Danmark – Ground floor
SIGN UP
Program
|
8:30 – 9:00
|
Registration & Coffee
|
|
9:00 – 9:05
|
Welcome
|
|
9:05 – 10:00
|
Using a ‘virtual pharma model’ to attract targeted investors for biotech innovators
– De-risk investment, de-risk operational delivery and maximize the return on investment (ROI) for all parties
Martin Gouldstone, SVP Syneos One
Tracy Weightman Principal Bridge Valley Ventures
Giles Dudley, Senior Business Developer, BioInnovation Institute (BII)
|
|
10:00 – 10:30
|
Networking
|
Speakers
 |
Martin Gouldstone, SVP Syneos One
- Seasoned executive with 30 years industry experience
- Leads Capital Solutions at Syneos One
- Specialized in valuations and buy/sell work encompassing trade and private equity as a Partner at Results Healthcare and as Head of Life Sciences at BDO UK
- Developed Capital Solutions and Partnerships where product based financing was required for Quintiles enterprise accounts
- Supported customer fund raising, spin-outs and due diligence support as Lead for the Product Strategy Practice at Quintiles
- Earlier career in Genetics, Clinical research and BD and Licensing lead in several discovery platform biotechs
|
 |
Tracy Weightman, Principal, Bridge Valley Ventures
- Over 15 years’ experience in venture capital, business development and project management
- Previously an Investment Associate at Epidarex Capital, a £50m UK-based life science venture fund, responsible for the closure of large Series A investments and several bridge financings
- Worked in business creation and business development functions at Edinburgh University and as a project manager for Quintiles
- Holds a BSc in Chemistry and an MBA, both from the University of Strathclyde
|
 |
Giles Dudley, Senior Business Developer, BioInnovation Institute (BII)
- Prior to BII, he previously held several leadership roles in the life science start up space from managing research based innovation projects through to helping companies secure private financing
- BII is a new arrival to the Copenhagen life science community. It provides up to 10m DDK of funding for early stage companies, as well as educational support through its business acceleration academy
- A key purpose of the BII is to help research based innovation address the technical, clinical and commercial risks that are required to help the company secure the next stage of funding
- Keen to reach out to entrepreneurs, inventors and management teams that could benefit being part of the BII community
|
|
Arranged by:
|
In collaboration with:
|
